With novel biologicals against alternative targets, such as ustekinumab (anti-IL12/23) and vedolizumab (anti-α4β7 integrin) for treatment of CD/IBD and thus possibility of greater stratification of the patients [6], pre-emptive prediction of non-response to anti-TNF is becoming even more meaningful. This evidence concerns the gene TNF and inflammatory bowel disease.